Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/00 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/205455SARS-COV2 CORONAVIRUS RECONSTITUTED RBM AND USES THEREOF
WO 14.10.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/IL2021/050402 Applicant RAMOT AT TEL-AVIV UNIVERSITY LTD. Inventor GERSHONI, Jonathan M.
The present invention relates to vaccines and therapeutic compositions targeted at coronaviruses, specifically, the Severe Acute Respiratory Syndrome coronavirus 2 (SARS CoV2). More specifically, the invention provides reconstituted Receptor Binding Motif (RBM) of a Spike protein of the SARS CoV2, Receptor Binding domains (RBDs), and spike proteins comprising the reconstituted RBMs or τ -linkers, compositions, vaccines, therapeutic and diagnostic methods and uses thereof.
2.WO/2021/156490CORONA VIRUS BINDERS
WO 12.08.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/EP2021/052885 Applicant VIB VZW Inventor SCHEPENS, Bert
The present invention relates to the field of virology, more specifically to the field of zoonotic Coronaviruses. Specifically, the invention provides for binding agents specific for the spike protein receptor binding domain (RBD) of the SARS-Corona virus, more specifically for an epitope of the RBD present in a broad range of Sarbecoviruses and mutants thereof, even more specifically present in SARS-Cov and SARS-CoV-2 viruses. More specifically, the invention relates to compositions comprising antibodies capable of specifically binding and neutralizing SARS-Corona viruses. More specifically the invention relates to compositions comprising single domain antibodies, or specifically VHHs, and compositions comprising multivalent binding agents comprising IgG Fc fusions thereof, specifically VHH-Fc fusions thereof, even more specifically comprising heavy chain only VHH72-S56A-IgG1-Fc fusions, or compositions comprising any humanized form of any one thereof, and are capable of specifically binding and neutralizing SARS-Corona viruses, specifically SARS-Cov-2 virus. The compositions are useful in the diagnosis of Sarbecoviruses, and specifically SARS-CoV-2 virus, and in prophylactic and/or therapeutic treatment of a condition resulting from infections with Sarbecoviruses, specifically SARS-Corona or SARS-CoV-2 virus, or mutants thereof.
3.WO/2022/147290CROSS-NEUTRALIZING SARS-COV2 ANTIBODIES
WO 07.07.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2021/065737 Applicant THE BROAD INSTITUTE, INC. Inventor XAVIER, Ramnik
The present invention provides for cross-neutralizing SARS-CoV2 antibodies. The antibodies can be used to treat SARS-CoV2 and variants thereof.
4.WO/2022/162012ANTIBODIES BROADLY TARGETING CORONAVIRUSES AND USES THEREOF
WO 04.08.2022
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Appl.No PCT/EP2022/051776 Applicant ETH ZURICH Inventor SALLUSTO, Federica
The present invention relates to antibodies, and antigen binding fragments thereof, that bind to the spike (S) protein of coronaviruses. The antibodies, and antigen binding fragments thereof, broadly target coronaviruses, including different alpha- and betacoronaviruses. The invention also relates to nucleic acids that encode, and to cells that express such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments in the treatment and diagnosis of coronavirus infection. Furthermore, a recombinant peptide, polypeptide or protein comprising the epitope, to which the antibodies bind to, is provided, which may be useful in vaccination.
5.WO/2022/167666SARBECOVIRUS BINDERS
WO 11.08.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/EP2022/052919 Applicant VIB VZW Inventor SAELENS, Xavier
The invention relates to agents binding to sarbecoviruses of multiple clades and potently neutralizing sarbecovirus infection, in particular neutralizing SARS-CoV-1 and SARS-CoV-2 infection. The agents bind to a unique epitope of the sarbecovirus ACE2-receptor binding domain (RBD) but do not inhibit binding of ACE2 with the RBD. Application and uses of these agents are further part of this invention.
6.WO/2021/216729CELLULAR VACCINE PLATFORM AND METHODS OF USE
WO 28.10.2021
Int.Class A61K 39/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
Appl.No PCT/US2021/028427 Applicant INTIMA BIOSCIENCE, INC. Inventor CHOUDHRY, Modassir
Cellular vaccine platforms, such as vaccine immune viral opsonization platforms, for eliciting host immune responses are disclosed. Also disclosed are the methods of making and using the cellular vaccine platforms in stimulating host immune responses.
7.WO/2022/152939CORONAVIRUS IMMUNOGENIC COMPOSITIONS, METHODS AND USES THEREOF
WO 21.07.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/EP2022/051018 Applicant CONSERV BIOSCIENCE LIMITED Inventor PLEGUEZUELOS, Olga
The present specification discloses broad-spectrum, pan-Coronavirus immunogenic composition including amino acid-based, broad-spectrum, pan-Coronavirus immunogenic compositions and nucleotide-based, broad-spectrum, pan-Coronavirus immunogenic compositions, methods and uses for preventing or treating a Coronavirinae-based infection or pathology as well as methods and uses of creating, maintaining or restoring antigenic memory to one or more Coronavirus species, strains, genotypes, subgenotypes, serotypes or genetic/antigenic lineages in an individual or population of individuals.
8.20220226465Coronavirus Immunogenic Compositions, Methods and Uses Thereof
US 21.07.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17648283 Applicant ConserV Bioscience Inventor Olga PLEGUEZUELOS MATEO

The present specification discloses broad-spectrum, pan-Coronavirus immunogenic composition including amino acid-based, broad-spectrum, pan-Coronavirus immunogenic compositions and nucleotide-based, broad-spectrum, pan-Coronavirus immunogenic compositions, methods and uses for preventing or treating a Coronavirinae-based infection or pathology as well as methods and uses of creating, maintaining or restoring antigenic memory to one or more Coronavirus species, strains, genotypes, subgenotypes, serotypes or genetic/antigenic lineages in an individual or population of individuals.

9.WO/2021/229591NOVEL USE OF NON-IONIC SURFACTANT FOR THE TREATMENT OF COVID–19
WO 18.11.2021
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/IN2020/050643 Applicant KRISHNAMACHARI, Ramu Inventor RITHVIK, K
The present invention relates to a novel use of non-ionic surfactants for the treatment of diseases caused by viruses. The present invention particularly relates to the use of non-ionic surfactants for the treatment of a disease known as COVID 19 caused by coronavirus SARS-CoV-2. The present invention further teaches the use of taste masking agents/excipients. The present invention is further believed to be related to cleansing the coronaviruses from buccal cavities, throat or within the body of a subject by not allowing the said virus to attach to any cells of mucosal layers or epithelial cells thus allowing them to pass out of the body or getting digested inside the body. For this reason the molecules or the composition used herein of the present invention is termed by the applicant as "INTERNAL SOAP".
10.WO/2022/117798IMMUNOGENIC COMPOSITIONS FOR PRODUCING NEUTRALISING ANTIBODIES AGAINST SARS-COV
WO 09.06.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/EP2021/084132 Applicant DEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN Inventor KRUGLOV, Andrey
The invention relates to an immunogenic composition for use as a medicament to prevent and/or treat a medical condition associated with a SARS-CoV infection, said composition comprising one or more bacteria of the human microbiota and/or immunogenic parts thereof, wherein said composition is capable of inducing acquired immunity to said infection. The invention further relates to isolated bacteria of the human microbiota that bind to a neutralising antibody that recognises the spike protein of SARS-CoV, preferably the spike protein of SARS-CoV2. In another aspect, the invention relates to an in vitro method for the diagnosis, prognosis, risk stratification and/or therapy management of a human subject with an increased risk of an adverse event associated with a medical condition associated with a SARS-CoV infection (preferably with SARS-CoV-2).